Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2008-09-30
2008-09-30
Kim, Jennifer (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S169000, C514S171000, C514S456000, C514S448000
Reexamination Certificate
active
10749981
ABSTRACT:
Novel methods for the medical treatment and/or inhibition of the development of osteoporosis, breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warm-blooded animals including humans involving administration of selective estrogen receptor modulator particularly compounds having the general structure:and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3β, 17β-diol and compounds converted in vivo to one of the foregoing presursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursor is disclosed for the medical treatment and/or inhibition of the development of osteoporosis. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.
REFERENCES:
patent: 3742951 (1973-07-01), Zaffaroni
patent: 3797494 (1974-03-01), Zaffaroni
patent: 4005200 (1977-01-01), Utsumi et al.
patent: 4496556 (1985-01-01), Orentreich
patent: 4542129 (1985-09-01), Orentreich
patent: 4568343 (1986-02-01), Leeper
patent: 4624665 (1986-11-01), Nuwayser
patent: 4666441 (1987-05-01), Andriola
patent: 4920115 (1990-04-01), Nestler et al.
patent: 5064654 (1991-11-01), Berner
patent: 5071644 (1991-12-01), Viegas
patent: 5071657 (1991-12-01), Oloff
patent: 5135480 (1992-08-01), Bannon
patent: 5154922 (1992-10-01), Govil
patent: 5162037 (1992-11-01), Whitson-Fischman
patent: 5354861 (1994-10-01), Sim
patent: 5362720 (1994-11-01), Labrie
patent: 5389646 (1995-02-01), Labrie
patent: 5391557 (1995-02-01), Cullinan
patent: 5393763 (1995-02-01), Black
patent: 5393785 (1995-02-01), Labrie
patent: 5395842 (1995-03-01), Labrie
patent: 5407947 (1995-04-01), Bryant et al.
patent: 5446071 (1995-08-01), Grese
patent: 5489587 (1996-02-01), Fontana
patent: 5523309 (1996-06-01), Bryant
patent: 5550107 (1996-08-01), Labrie
patent: 5567828 (1996-10-01), Dodge
patent: 5686465 (1997-11-01), Labrie
patent: 5728688 (1998-03-01), Labrie
patent: 5840735 (1998-11-01), Labrie et al.
patent: 5843984 (1998-12-01), Clay et al.
patent: 6465445 (2002-10-01), Labrie
patent: 6511970 (2003-01-01), Rodriguez
patent: 6670346 (2003-12-01), Labrie
patent: 7005428 (2006-02-01), Labrie
patent: 3826297 (1989-02-01), None
patent: 4401554 (1994-08-01), None
patent: 279982 (1988-08-01), None
patent: 635264 (1995-01-01), None
patent: 651998 (1995-05-01), None
patent: 652002 (1995-05-01), None
patent: 652007 (1995-05-01), None
patent: 657162 (1995-06-01), None
patent: 665015 (1995-08-01), None
patent: 674903 (1995-10-01), None
patent: 693285 (1996-01-01), None
patent: 703231 (1996-03-01), None
patent: 712628 (1996-05-01), None
patent: 724881 (1996-08-01), None
patent: 729955 (1996-09-01), None
patent: 747380 (1996-12-01), None
patent: 0 781 555 (1997-07-01), None
patent: 791591 (1997-08-01), None
patent: 793961 (1997-09-01), None
patent: 801066 (1997-10-01), None
patent: 802183 (1997-10-01), None
patent: 802184 (1997-10-01), None
patent: 806420 (1997-11-01), None
patent: 1 246 639 (1971-09-01), None
patent: 2 185 187 (1987-07-01), None
patent: P 99 002847 (1992-01-01), None
patent: 208150 (1993-08-01), None
patent: P 95 00229 (1996-05-01), None
patent: P 95 01985 (1996-07-01), None
patent: P 98 01230 (1999-06-01), None
patent: A-8-505629 (1996-06-01), None
patent: A-10-36347 (1998-02-01), None
patent: A-10-147522 (1998-06-01), None
patent: A-10-511961 (1998-11-01), None
patent: A-11-500133 (1999-01-01), None
patent: A-2000-505444 (2000-05-01), None
patent: WO 8601105 (1986-02-01), None
patent: WO 9010462 (1990-09-01), None
patent: WO 9300070 (1993-01-01), None
patent: WO 93/10741 (1993-06-01), None
patent: WO 9416709 (1994-08-01), None
patent: WO 9600041 (1996-01-01), None
patent: WO 96/05833 (1996-02-01), None
patent: WO 9605824 (1996-02-01), None
patent: WO 9605825 (1996-02-01), None
patent: WO 9605829 (1996-02-01), None
patent: WO 9607402 (1996-03-01), None
patent: WO 9609040 (1996-03-01), None
patent: WO 9616646 (1996-06-01), None
patent: WO 9626201 (1996-08-01), None
patent: WO 9725034 (1997-07-01), None
patent: WO 9725035 (1997-07-01), None
patent: WO 9725036 (1997-07-01), None
patent: WO 9725037 (1997-07-01), None
patent: WO 9725038 (1997-07-01), None
patent: WO 9732837 (1997-09-01), None
patent: WO 98/58948 (1998-12-01), None
patent: WO 99/59581 (1999-11-01), None
patent: WO 99/63973 (1999-12-01), None
Blum et al. The influence of topical vaginal estrogen application on the lipids metabolism Gynecol. obstet. Invest. 15: 10-15 (1983) pp. 10-15.
Calin Chen et al., “Adrenal Steroid Precursors Exert Potent Androgenic Action in the Hamster Sebaceous Glands of Flank Organs and Ears”,Endocrinology137: 1752-1757, 1996.
Claude Labrie et al., “Stimulation of Androgen-Dependent Gene Expression by the Andrenal Precursors Dehydroepiandrosterone and Androstenedione in the Rat Ventral Prostate”,Endocrinology124: 2745-2754, 1989.
Claude Labrie et al., “Androgenic Activity of Dehydroepiandrosterone and Androstenedione in the Rat Ventral Prostate”,Endocrinology123: 1412-1417, 1988.
Delmas et al.,N. Engl. J. Med., Dec. 4, 1997; vol. 337(23), pp. 1641-1647.
N. Engl. J. Med., 1998, vol. 319, pp. 1681-1692.
F. Labrie et al., “DHEA and the Intracrine Formation of Androgens and Estrogens in Peripheral Target Tissues: Its Role During Aging,”Steroids, 53:322-328 (1998).
F. Labrie et al., “Interactions Between Estrogens, Androgens, Progestins, and Glucocorticoids in ZR-75-1 Human Breast Cancer Cells,”Annals New York Academy of Sciences, pp. 130-148, 1990.
S. Luo et al., “Prevention of Development of Dimethylbenz(a)anthracene (DMBA)—Induced Mammary Tumors in the Rat by the New Nonsteroidal Antiestrogen EM-800 (SCH57050),”Breast Cancer Research and Treatment, 49:1-11 (1998).
Schwartz et a., “Dehydroepiandrosterone: an anti-obesity and anti-carcinogenic agent”,Nutr. Cancer1981, 31 (1), 46-53 ISSN: 01635581.
Couillard, S,; Labrie, C.; Gauthier, S.; Labrie, F., Abstract,Maturitas, (1997), vol. 27, No. SUPPL., pp. 80, Title: “Inhibitory Effect of a new Non-Steroidal Pure Antiestrogen (EM-800) in Combination with DHEA on Human ZR-75-1 Breast Tumors in Nude Mice”.
Adami, S., Baroni, M.C., Broggini, M., Carratelli, L., Caruso, I., Gnessi, L., laurenzi, M., Lombardi, A., Norbiato, G., Ortolani, S., Ricerca, E., Romanini, L., Subrizi, S., Weinberg, J., Yates, A.J. (1993) Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporosis Int. (Suppl.), 3: S21-S27.
Adams, J., Garcia, M., Rochefort, H. (1981 Estrogenic effects of physiological concentrations of 5-androstene-3β,17b-diol and its metabolism in MCF7 human breast cancer cells. Cancer Res., 41: 4720-4926.
Alison, R.H., Morgan, K.T., Montgomery Jr, C.A. Chapter 26: Ovary.In: Boorman, G.A., Eutis, S.L., Elwell, M.R., Montgomery Jr, C.A. and MacKenzie, W.F., eds, Pathology of the Fischer Rat, pp. 429-442, San Diego: Academic Press, 1990.
Arad, Y., Badimon, J.J., Badimon, L., Hembree, W.C., Ginsberg, H.N. (1989) Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbit. Arteriosclerosis, 9: 159-166.
Asselin, J., Kelly, P.A., Caron, M.G., Labrie, F. (1977) Control of hormone receptor levels and growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors by estrogens, progesterone and prolactin. Endocrinology, 101: 666-671.
Balena, R., Toolan, B.C., Shea, M., Markatos, A., Myers, E.R., Lee, S.C., Opas, E.E., Seedor, J.G., Klein, H., Frankenfield, D., Quartuccio, H., Fioravanti, C., Clair, J., Brown, E., Hayes, W.C., Rodan, G.A. (1993) The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry and bone strength in ovariectomized nonhuman primates. J. Clin. Invest., 92: 2577-2586.
Baran, D.T., Bergfeld, M.A., Teitelbaum, S.L.
Endorecherche Inc.
Kim Jennifer
OStrolenk, Faber, Gerb & Soffen, LLP
LandOfFree
Medical uses of a selective estrogen receptor modulator in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medical uses of a selective estrogen receptor modulator in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medical uses of a selective estrogen receptor modulator in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3943212